151.97
Moderna Inc 주식(MRNA)의 최신 뉴스
Experimental mRNA cancer vaccine treatment pass a key test, sending Moderna stocks surging - ketv.com
Moderna, Inc. (NASDAQ: MRNA) Hits Day's High of $163.47 on News - Investorideas.com
Watch Moderna Surges on Cancer Vaccine; Estee Lauder Rallies on Earnings | Stock Movers - Bloomberg.com
Top Midday Stories: Treasury Lifts Buyback Cap on Long-Dated Securities; Moderna, Merck Say Melanoma Vaccine Meets Primary Endpoint in Trial - Moomoo
US Markets Rise as Semiconductor Stocks Surge, Moderna (MRNA) Re - GuruFocus
US Open: Market Tries to Regain Ground, Moderna Up 140% (19.08.2026) - xtb.com
Moderna Cancer Vaccine Buzz Is Shining A Light On Smaller Immuno Oncology Stocks - simplywall.st
From COVID to Cancer: Moderna Scores Melanoma Breakthrough - Zacks Investment Research
Cancer vaccine shows promise in late- stage melanoma trial; stocks soar - newsnationnow.com
Goldman Sachs Adjusts Price Target on Moderna to $120 From $67, Keeps Neutral Rating - marketscreener.com
Moderna short sellers face $4.8 billion loss amid record stock jump - Investing.com
Moderna Moves Back Toward Covid-Era Valuation With Latest mRNA Update - marketscreener.com
Moderna's Cancer Vaccine Win Is Merck's Story Too - Benzinga
MRNA Looks 532.5% Overvalued on GF Value™ After Cancer Vaccine T - GuruFocus
Moderna Stock's Best Day Ever After Cancer Trial WinModerna (NASDAQ:MRNA) - Benzinga
Tempus AI Soars as Merck-Moderna Cancer Trial Validates Personalis Acquisition - Benzinga
Moderna stock more than doubles after melanoma vaccine trial shows "landmark moment" - CBS News
Moderna Stock Price Soars 160% on Melanoma Vaccine Success - businessinsider.com
Moderna, Merck mRNA cancer vaccine prevents melanoma from returning - The Hill
Moderna and Merck & Co, the day's Wall Street standouts - marketscreener.com
Moderna stock skyrockets after landmark Phase 3 melanoma readout - Quiver Quantitative
MRNA Looks 470.2% Overvalued on GF Value™ - GuruFocus
VIEW Moderna-Merck melanoma vaccine data boosts outlook, but analysts await full results - Reuters
Moderna-Merck melanoma vaccine data boosts outlook, but analysts await full results - TradingView
Moderna & Merck stocks skyrocket on their cancer vaccine trial's success. Here's what to know. - Yahoo Finance UK
Moderna-Merck melanoma therapy averts cancer recurrence in study - Chicago Tribune
S&P500: Treasury Buyback Lifts US Stocks as Moderna Cancer Data Sparks Rally - FXEmpire
Moderna shares soar as mRNA cancer vaccine succeeds in late-stage trial - Proactive financial news
Brookline reiterates Moderna stock rating on positive melanoma data - Investing.com
Moderna shares skyrocket nearly 100% on melanoma drug trial success - Investing.com
U.S. Treasury Doubles Long-Term Bond Buybacks; Stocks Open Higher as Moderna Soars Over 80% - finance.biggo.com
Moderna (MRNA) Shares Surge Over 90% After Successful Skin Cance - GuruFocus
Moderna Stock Eyes Best Day Ever After Cancer Vaccine Breakthrough - Schaeffer's Investment Research
Moderna’s experimental vaccine prevents cancer recurrence, in ‘historic’ win for personalized medicine. Its stock is soaring. - MarketWatch
MRNA Looks 389.5% Overvalued on GF Value™ After Cancer Trial Sur - GuruFocus
Moderna surges on trial win for cancer shot; William Blair upgrades - Seeking Alpha
Moderna Stock Explodes Over 100% After Cancer Vaccine Breakthrough - Yahoo Finance
Moderna stock more than doubles on Phase 3 win: Time to take profits? - Investing.com
Moderna skyrockets 120% on melanoma treatment - Breakingthenews.net
Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday - Benzinga
Moderna takes off, while Trainline and Rockwool under pressure - marketscreener.com
Moderna Stock Jumps 86% on First mRNA Cancer Trial Win - GuruFocus
Wall St up after tech selloff as yields retreat; Moderna surges - marketscreener.com
Moderna’s Cancer Breakthrough Sends the Stock Soaring 84% - barrons.com
Merck jumps by 10% on melanoma vaccine update - Breakingthenews.net
MRNA Looks 159.3% Overvalued on GF Value™ - GuruFocus
Moderna (NASDAQ:MRNA) Hits New 12-Month High Following Analyst Upgrade - MarketBeat
Moderna stock hits 52-week high at 115.6 USD - Investing.com
Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal - BioSpace
Moderna shares jump over 90% after cancer vaccine shows positive Phase 3 results - CNBC TV18
Moderna Rockets 93%, Merck Jumps 7% as Melanoma Therapy Meets Primary Goal in Phase 3 Trial - Yahoo Finance
Moderna, Merck, SK Hynix, Micron, Target, Estée Lauder, and More Stocks That Explain Today’s Market - barrons.com
MRNA Gains New Catalyst As FDA Clears mFLUSIVA Flu Shot - timothysykes.com
Healthcare ETFs rally as Moderna nearly doubles on melanoma win - Seeking Alpha
MRNA Looks 159.3% Overvalued on GF Value™ Amid Premarket Surge - GuruFocus
MRNA Looks 159.3% Overvalued on GF Value™ as Price-to-Sales Soars Amid Trial Optimism - GuruFocus
Moderna, Inc. stock Analysis: Daily Bullish Trend and Key Catalyst - The Cryptonomist
Merck & Company, Inc. stock Analysis: Daily Trend & Vaccine Impact - The Cryptonomist
William Blair Upgrades Moderna to Outperform From Market Perform - marketscreener.com
Moderna (NASDAQ:MRNA) Stock Rating Upgraded by William Blair - MarketBeat
Moderna surges as Merck-partnered melanoma vaccine cuts recurrence in large trial - ca.finance.yahoo.com
Wall St set for higher open after retail earnings; Moderna soars - Yahoo Finance
Moderna's mRNA Vaccine Trial Success Boosts Stock (MRNA) - GuruFocus
Moderna Stock Rockets Higher After Positive Cancer Vaccine Trial Data - Investopedia
Why is Moderna stock surging today? By Investing.com - Investing.com South Africa
Moderna Surges Over 100% Pre-Market as Phase 3 Cancer Vaccine Trial With Merck Succeeds - TradingKey
Moderna Shares Skyrocket 125% Toward Best Day Ever—On Success Of Cancer Drug Trial - Yahoo Finance UK
MRNA Stock Jumps As FDA Clears New Flu Vaccine - StocksToTrade
Why Moderna stock is rocketing today - Finbold
Moderna (MRNA) and Merck Achieve Milestone with Personalized Can - GuruFocus
Moderna shares soar after major cancer vaccine breakthrough - NBC Boston
Moderna's personalized cancer vaccine shows success in Phase 3 trial - The Business Journals
자본화:
|
볼륨(24시간):